Zelluna ASA (OSTO:ULTIO) EBIT: kr-130.90 Mil (TTM As of Mar. 2026)

What is Zelluna ASA EBIT?

Zelluna ASA OSTO:ULTIO 28 EBIT is kr-130.90 Mil as of Mar. 2026. GuruFocus rates OSTO:ULTIO with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Zelluna ASA's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr-20.04 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-130.90 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zelluna ASA's annualized ROC % for the quarter that ended in Mar. 2026 was -50.94%. Zelluna ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -5,855.37%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zelluna ASA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -30.50%.

Zelluna ASA (OSTO:ULTIo) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zelluna ASA's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-81.372 * ( 1 - 0% )	/	( (296.709	+	22.774)	/ 2 )
=	-81.372	/	159.7415
=	-50.94 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	308.07	-	5.087	-	( 12.626	-	max(0, 7.65	-	13.924	+	12.626	))
=	296.709

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	75.838	-	3.72	-	( 49.344	-	max(0, 8.802	-	59.013	+	49.344	))
=	22.774

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Zelluna ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-80.16	/	( ( (0.006 + max(-7.134, 0))	+	(2.732 + max(-6.484, 0)) )	/	2 )
=	-80.16	/	( ( 0.006	+	2.732 )	/	2 )
=	-80.16	/	1.369
=	-5,855.37 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.516)	-	(5.087	+	0	+	2.563)
=	-7.134

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.965)	-	(3.72	+	0	+	4.729)
=	-6.484

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zelluna ASA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-130.899	/	429.119
	=	-30.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA EBIT Related Terms

Zelluna ASA EBIT Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's EBIT can be seen below:

Zelluna ASA EBIT Chart

Zelluna ASA Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-163.83

-183.63

-215.73

-105.12

-140.61

Zelluna ASA Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-27.98	-37.13	-39.22	-34.51	-20.04

OSTO:ULTIO vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Zelluna ASA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zelluna ASA EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zelluna ASA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zelluna ASA's EV-to-EBIT falls into.

Save Embed

28GF Score

Zelluna ASA OSTO:ULTIO

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Zelluna ASA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-130.90 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of kr-130.90 Mil mean?

Zelluna ASA (OSTO:ULTIO) has a EBIT of kr-130.90 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zelluna ASA.

Is Zelluna ASA's EBIT too high?

Zelluna ASA's current EBIT is kr-130.90 Mil. Overall, Zelluna ASA has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.

How does Zelluna ASA's EBIT compare to VRTX and REGN?

Zelluna ASA's EBIT of kr-130.90 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Zelluna ASA. Zelluna ASA's current EBIT is kr-130.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Zelluna ASA stock overvalued right now?

Zelluna ASA (OSTO:ULTIO) has a current EBIT of kr-130.90 Mil. The current EBIT is kr-130.90 Mil. Zelluna ASA's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Zelluna ASA (OSTO:ULTIO), the current EBIT is kr-130.90 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Industry Healthcare Biotechnology

Comparable Companies OSL:LYTIX OSL:SOFTX OSL:ONCIN OSL:NYKD OSL:EXTX OSL:ABS OSL:ABTEC OSL:AZT OSL:TRMED OSL:CRNA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ZLNA:Norway 7UM0:Germany

Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379

Website https://www.zelluna.com

Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.

28GF Score

Get the complete analysis for OSTO:ULTIO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr21.95

Price

View OSTO:ULTIO Analysis

See EBIT data for all stocks →